Novartis Doses First Patient in Phase 2 Sjögren's Trial of VAV1 Degrader MRT-6160, Triggering $50M Payment to Monte Rosa
核心洞察
Monte Rosa Therapeutics received a $50 million milestone payment from Novartis after the first patient was dosed in a Phase 2 trial of MRT-6160 in Sjögren's disease (搜索).
MRT-6160 (DDY391 (搜索)) is an oral molecular glue degrader of VAV1 (搜索) that achieved over 90% target degradation in a Phase 1 study without serious adverse effects.
The Novartis agreement includes up to $2.1 billion in development, regulatory and sales milestones, with Novartis funding all Phase 2 studies.
Novartis has dosed the first patient in a global Phase 2 study of MRT-6160 (DDY391 (搜索)) in Sjögren's disease (搜索), triggering a $50 million milestone payment to partner Monte Rosa Therapeutics, the clinical-stage biotechnology company announced on September 8, 2026. The payment is the first to convert under a global exclusive development and commercialization license agreement between the two companies covering VAV1 (搜索)-directed molecular glue degraders (MGDs), a deal that carries up to $2.1 billion in development, regulatory and sales milestones.
The milestone marks the program's transition from Phase 1 into late-stage clinical development and represents the clearest signal yet that Novartis believes VAV1 (搜索) degradation works in humans, according to Clinical Trial Vanguard.
A Molecular Glue Degrader Targeting VAV1
MRT-6160 is a potent, highly selective, and orally bioavailable investigational molecular glue degrader of VAV1 (搜索), a key signaling protein downstream of both the T- and B-cell receptors. Monte Rosa states that available preclinical and clinical data support the molecule's potential to address multiple immune-mediated diseases.
In a Phase 1 study, MRT-6160 demonstrated sustained, dose-dependent VAV1 (搜索) degradation of greater than 90% in peripheral blood T cells after single and multiple-dose administration, along with suppression of key inflammatory biomarkers. Administration of the drug was generally well tolerated, with no serious adverse effects observed.
The Phase 2 study will track participants for as long as one year of treatment, comparing MRT-6160 against placebo across multiple sites to identify the appropriate dose before a Phase 3 program begins. Novartis is conducting and funding the trial in full. Monte Rosa remains eligible to collect further payments each time a new Phase 2 study opens for MRT-6160 in other immune conditions, an arrangement that allows the drug to advance without drawing on Monte Rosa's own cash.
Sjögren's Disease: A Large, Underdiagnosed Target
Sjögren's disease (搜索) is a serious, progressive autoimmune disease affecting approximately 0.25% of the population. It impacts multiple organs and causes a wide spectrum of symptoms including dryness, fatigue, pain, and an increased risk of lymphoma (搜索), which can carry a significant burden and impact on quality of life. Its heterogeneous nature often causes it to go unrecognized or misdiagnosed; an estimated 50% of people with Sjögren's disease are undiagnosed.
The condition drives chronic inflammation through autoreactive B and T cells, and VAV1 (搜索) sits upstream in the signaling cascade that keeps those cells active. Approved options for Sjögren's remain limited, with disease-modifying candidates from multiple companies still in mid-to-late development. Novartis conducting the study globally raises the enrollment ceiling and positions MRT-6160 for a broad regulatory path if Phase 2 reads out favorably.
Terms of the Novartis Collaboration
Under the agreement, Novartis holds exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1 (搜索) MGDs, and is responsible for all clinical development and commercialization starting with Phase 2 studies. Monte Rosa will co-fund any Phase 3 clinical development and will share 30% of profits and losses associated with the manufacturing and commercialization of MRT-6160 in the U.S., and is also eligible for tiered royalties on ex-U.S. net sales.
Broader Pipeline and Financial Position
The VAV1 (搜索) asset is not carrying Monte Rosa alone. On August 6, the company reported that enrollment and dosing had wrapped up in its GFORCE-1 study of MRT-8102 in people with elevated cardiovascular risk, with results due later in 2026, building on earlier findings of an 85% median drop in CRP after just four weeks of treatment. Monte Rosa also initiated its MODeFIRe-1 study, pairing MRT-2359 with the prostate cancer (搜索) drug apalutamide in patients whose tumors carry androgen receptor (搜索) mutations.
Monte Rosa's QuEEN (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with high selectivity. The company describes its pipeline as spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic, and reports ongoing collaborations with leading pharmaceutical companies in immunology, oncology, and neurology.
Backing these programs is $626 million in cash, equivalents, and marketable securities as of June 30, which management says can fund operations into 2029.
Rising Costs and Widening Losses
The progress has come at a cost. Revenue from Monte Rosa's collaborations dropped to $9.0 million in the second quarter of 2026 from $23.2 million a year earlier, while research spending rose to $48.0 million from $30.7 million and administrative costs climbed to $10.1 million from $8.1 million. Combined, the quarterly net loss ballooned to $43.4 million, more than triple the $12.3 million loss reported for the same period in 2025.
For trial watchers, the key question now concerns the Phase 2 design itself: which endpoints Novartis selected, whether the primary measure is symptom-based or biomarker-driven, and how long the treatment period runs. Degrader programs depend on proof of target engagement in humans, and a Phase 2 in an autoimmune setting will generate that pharmacodynamic data whether or not it hits clinical endpoints.